Increase in peripheral blood mononuclear cell (PBMC)- and CD56+ cell-mediated killing of endometrial stromal cells by mycobacteria; a possible role in endometriosis immunotherapy?

Human Reproduction

Volumn 19, Issue 8, 2004, Pages 1886-1893

  Clayton, R D ^a,c   Duffy, S R ^a   Wilkinson, N ^a   Garry, R ^a,b   Jackson, A M ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

BCG; Endometriosis; Endometrium

Indexed keywords

BCG VACCINE; CD56 ANTIGEN; CELL EXTRACT;

ADULT; ARTICLE; BACILLUS; BACTERIAL STRAIN; CELL CULTURE; CELL GROWTH; CELL KILLING; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EFFECTOR CELL; ENDOMETRIOSIS; ENDOMETRIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; IN VITRO STUDY; MYCOBACTERIUM SMEGMATIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; STROMA CELL; TARGET CELL; VOLUNTEER;

CORYNEBACTERINEAE; MYCOBACTERIUM BOVIS BCG;

EID: 4344580881     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh340     Document Type: Article

References (25)

1. Acien P, Quereda F, Campos A, Gomez-Torres MJ, Velasco I and Gutierrez M (2002) Use of intraperitoneal interferon alpha-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil Steril 78,705-711.
2. Agarwala SS and Kirkwood JM (2000) Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova) 10,230-239.
3. Alexandroff AB, Jackson AM, O'Donnell MA and James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353,1689-1694.
4. Ali AF, Fateen B, Ezzet A, Badawy H, Ramadan A and El-tobge A (2000) Laparoscopic intraperitoneal injection of human interferon-alpha2b in the treatment of pelvic endometriosis: a new modality. Obstet Gynecol 95,S47-S48.
5. Bohle A (2000) BCG's mechanism of action - increasing our understanding. For the EBIN Group. Eur Urol 37 Suppl 1,1-8.
6. Bottle A, Thanhauser A, Ulmer AJ, Ernst M, Flad HD and Jocham D (1993) Dissecting the immunobiological effects of Bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150,1932-1937.
7. Clayton RD, Duffy SR, Wilkinson N, Garry R and Jackson AM (2004) Antiproliferative effect of mycobacteria, IFN-gamma and TNF-alpha on primary cultures derived from endometrial stroma: possible relevance to endometriosis? Am J Reprod Immunol 51,63-70.
8. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM and Strober W (1994) Assays for T cell function. In Coico R (ed.) Current Protocols in Immunology. John Wiley, New York, pp. 3.11.4-3.11.15.
9. D'Hooghe TM and Hill JA (1995) Killer cell activity, statistics, and endometriosis [letter; comment]. Fertil Steril 64,226-228.
10. Gleicher N (1995) Immune dysfunction-a potential target for treatment in endometriosis. Br J Obstet Gynaecol 102 Suppl 12,4-7.
11. Gul A, Yasar T and Ugras S (2001) BCG vaccination to prevent implantation of endometriosis: an experimental study in rats. Eur J Obstet Gynecol Reprod Biol 98,209-212.
12. Haley JL, Young DG, Alexandroff A, James K and Jackson AM (1999) Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha. Immunology 96,114-121.
13. Hornstein MD, Hemmings R, Yuzpe AA and Heinrichs WL (1997) Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 68,860-864.
14. Ingelmo JM, Quereda F and Acien P (1999) Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-alpha-2b in a routine model. Fertil Steril 71,907-911.
15. Jackson AM and Murphy M (1998) The use of mycobacteria for the delivery of cytokines in gene therapy. Curr Res Mol Ther 1,256-261.
16. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR and Bukovsky A (1999) Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 72,135-141.
17. Lamm DL (1992) Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 19,565-572.
18. Luo Y, Chen X, Downs TM, DeWolf WC and O'Donnell MA (1999) IFN-alpha 2B enhances Th1 cytokine, responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy. J Immunol 162,2399-2405.
19. Luo Y, Chen X, Han R and O'Donnell MA (2001) Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123, 264-270.
20. Noyes RW, Hertig AT, Rock J (1975) Dating the endometrial biopsy. Am JOG 122 (2),262-263.
21. O'Donnell MA (1997) The genetic reconstruction of BCG as a new immunotherapeutic tool. Trends Biotechnol 15,512-517.
22. Thanhauser A, Bohle A, Flad HD, Ernst M and Mattern T ander AJ (1993) Induction of bacillus-Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37,105-111.
23. Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C and Sismondi P (1999) A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symotomatic endometriosis. Br J Obstet Gynaecol 106,672-677.
24. Vigano P, Di Blasio AM, Dell'Antonio G and Vignali M (1993) Culture of human endometrial cells: a new simple technique to completely separate epithelial glands. Acta Obstet Gynecol Scand 72,87-92.
25. Witz CA (1999) Current concepts in the pathogenesis of endometriosis. Clin Obstet Gynecol 42,566-585.